KLTO - Klotho Neurosciences, Inc.


0.1648
0.010   5.825%

Share volume: 208,595
Last Updated: 04-07-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.02%

PREVIOUS CLOSE
CHG
CHG%

$0.16
0.01
0.06%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
20%
Profitability 0%
Dept financing 25%
Liquidity 20%
Performance 40%
Company vs Stock growth
vs
Performance
5 Days
-6.95%
1 Month
-40.87%
3 Months
-63.22%
6 Months
-62.65%
1 Year
-62.65%
2 Year
-62.65%
Key data
Stock price
$0.16
P/E Ratio 
0.00
DAY RANGE
$0.13 - $0.17
EPS 
-$0.21
52 WEEK RANGE
$0.11 - $0.95
52 WEEK CHANGE
-$62.65
MARKET CAP 
10.923 M
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-15-2025
BETA 
0.73
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$291,132
AVERAGE 30 VOLUME 
$132,051
Company detail
CEO: Joseph Sinkule
Region: US
Website: klothoneuro.com
Employees: 0
IPO year: 2022
Issue type:
Market: NASDAQ
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.

Recent news
loading